$3.9998
0.7498[23.07%]
At close: Apr 11
$3.9998
0[0.00%]
After Hours: 8:23AM EDT
MEI Pharma
(NASDAQ:MEIP)MEI Pharma Stock (NASDAQ:MEIP), Analyst Ratings, Price Targets, Predictions
MEI Pharma Inc has a consensus price target of $13.01, established from looking at the 16 latest analyst ratings. The last 3 analyst ratings were released from Stifel, Stifel, and Stifel on April 12, 2024, February 14, 2024, and September 27, 2023. With an average price target of $7.67 between Stifel, Stifel, and Stifel, there's an implied 91.68% upside for MEI Pharma Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Stifel
Brookline Capital
HC Wainwright & Co.
Jefferies
BTIG
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for MEI Pharma
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/12/2024 | MEIP | Buy Now | MEI Pharma | $4.00 | 75.01% | Stifel | Stephen Willey | $7 → $7 | Maintains | Hold | Get Alert |
| 02/14/2024 | MEIP | Buy Now | MEI Pharma | $4.00 | 75.01% | Stifel | Stephen Willey | $8 → $7 | Maintains | Hold | Get Alert |
| 09/27/2023 | MEIP | Buy Now | MEI Pharma | $4.00 | 125.01% | Stifel | Stephen Willey | $10 → $9 | Maintains | Hold | Get Alert |
| 05/23/2023 | MEIP | Buy Now | MEI Pharma | $4.00 | 1900.1% | Brookline Capital | Leah Cann | → $80 | Maintains | Buy | Get Alert |
| 05/12/2023 | MEIP | Buy Now | MEI Pharma | $4.00 | 150.01% | Stifel | Stephen Willey | $0.5 → $10 | Maintains | Hold | Get Alert |
| 02/13/2023 | MEIP | Buy Now | MEI Pharma | $4.00 | -50% | HC Wainwright & Co. | Andrew Fein | $100 → $40 | Maintains | Buy | Get Alert |
| 02/08/2023 | MEIP | Buy Now | MEI Pharma | $4.00 | -97.5% | Jefferies | Chris Howerton | $8 → $2 | Downgrade | Hold → Underperform | Get Alert |
| 12/06/2022 | MEIP | Buy Now | MEI Pharma | $4.00 | — | BTIG | Justin Zelin | — | Downgrade | Buy → Neutral | Get Alert |
| 12/06/2022 | MEIP | Buy Now | MEI Pharma | $4.00 | — | Truist Securities | Robyn Karnauskas | — | Downgrade | Buy → Hold | Get Alert |
| 03/25/2022 | MEIP | Buy Now | MEI Pharma | $4.00 | 0.01% | BTIG | Justin Zelin | $220 → $80 | Maintains | Buy | Get Alert |
| 03/25/2022 | MEIP | Buy Now | MEI Pharma | $4.00 | -25% | Truist Securities | Robyn Karnauskas | $160 → $60 | Maintains | Buy | Get Alert |
| 03/25/2022 | MEIP | Buy Now | MEI Pharma | $4.00 | 25.01% | HC Wainwright & Co. | Andrew Fein | $200 → $100 | Maintains | Buy | Get Alert |
| 03/25/2022 | MEIP | Buy Now | MEI Pharma | $4.00 | -50% | Wells Fargo | Jim Birchenough | $260 → $40 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 03/25/2022 | MEIP | Buy Now | MEI Pharma | $4.00 | -50% | Stifel | Stephen Willey | $120 → $40 | Downgrade | Buy → Hold | Get Alert |
| 03/25/2022 | MEIP | Buy Now | MEI Pharma | $4.00 | -75% | Jefferies | Chris Howerton | $80 → $20 | Downgrade | Buy → Hold | Get Alert |
| 02/03/2022 | MEIP | Buy Now | MEI Pharma | $4.00 | 0.01% | Jefferies | Chris Howerton | → $80 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for MEI Pharma (MEIP)?
The latest price target for MEI Pharma (NASDAQ: MEIP) was reported by Stifel on April 12, 2024. The analyst firm set a price target for $7.00 expecting MEIP to rise to within 12 months (a possible 75.01% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for MEI Pharma (MEIP)?
The latest analyst rating for MEI Pharma (NASDAQ: MEIP) was provided by Stifel, and MEI Pharma maintained their hold rating.
When was the last upgrade for MEI Pharma (MEIP)?
There is no last upgrade for MEI Pharma.
When was the last downgrade for MEI Pharma (MEIP)?
The last downgrade for MEI Pharma Inc happened on February 8, 2023 when Jefferies changed their price target from $0.4 to $0.1 for MEI Pharma Inc.
When is the next analyst rating going to be posted or updated for MEI Pharma (MEIP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MEI Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MEI Pharma was filed on April 12, 2024 so you should expect the next rating to be made available sometime around April 12, 2025.
Is the Analyst Rating MEI Pharma (MEIP) correct?
While ratings are subjective and will change, the latest MEI Pharma (MEIP) rating was a maintained with a price target of $7.00 to $7.00. The current price MEI Pharma (MEIP) is trading at is $4.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.